Sars Cov 2 Antigen Test Suppliers and Manufacturers

Weight: 25.5g/ kit Packaging: 300kits/carton Weight of carton: 8.6kg/carton

SARS-CoV-2 Antigen Test Kit CRDLIGHT 25 pcs/ box 5 pcs/ box

One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is intended for the qualitative detection of nucleocapsid protein antigen from SARS-in serum, plasma or whole blood samples from patients suspected of COVID-19 infection by a healthcare provider. A kit contains: Package specifications: 25 tests/box 1) Getein SARS-CoV-2 antigen test card in a sealed pouch with desiccant 2) Sample extraction solution: 25 tubes/box 3) Sampling swab: 25 pieces/box 4) Disposable pipette: 25 pieces/box 5) User manual: 1 piece/box

PocRoc SARS-CoV-2 Antigen Rapid Test Kit (TRFIA) is intended for qualitative detection of SARS-CoV-2 nucleocapsid antigen from NS specimen or VTM sample without guanidine -Target: nucleocapsid antigen -Specimens: Nasal Swab (NS) /Oropharynge al Swab(OP) Virus Transport Medium (VTM) - Time: Specimen lysis time: 1min; Detection Time: 15min -Instrument: LTRIC-300,LTRIC-600,UV Flashlight -Shelf Time: 18months -LoD: Estimated 25 TCID50/Swab

The FlowFlex Rapid Antigen Test uses the latest patented technology to detect proteins in nasal samples, ensuring that it can detect all strains of the COVID-19 virus within just 15 minutes. Using a simple nasal swab with 2cm of the nose - it makes it extremely easy to personally administer an accurate lateral flow test without medical supervision. Each individually packaged kit comes complete with: 1 x Test Cassette 1 x Extraction Buffer Tube with Reagent 1 x Disposable Swab 1 x Waste Bag 1 x Package Insert Performance Efficacy: Relative Sensitivity: 97.1% (83.8%-99.9%)* Relative Specificity: 99.6% (97.7%-99.9%)* Accuracy: 99.3% (97.5%-99.9%)* *95% Confidence Intervals

The lab indicated that the recombinant protein of Indian mutant (B.1.617.2), A.23.1(Unit Kingdom), AT.1 (Russia), B.1.1.7(Unit Kingdom), B.1.351 (South Africa), B.1.616 (France), B.1.621 (Colombia), C.36 (Egypt), C.37 (Peru), P.1 (Japan/Brazil), P.2 (Brazil) can be detected by Jinwofu SARS-CoV-2 Antigen Test Kit. For the newly descovered mutant Omicron(B.1.1.529), we performed sequence alignment analysis on its mutation sites, and found that all the mutation sites were outside the epitope region recognized by the monoclonal antibody selected by our company. By bioinformatics analysis, Jinwofu SARS-CoV-2 Antigen Test Kit can also effectively detect mutant Omicron(B.1.1529)

The kit is used to qualitatively detect the novel coronavirus (SARS-CoV-2) nucleocapsid protein antigen in human nasal swab samples in vitro. In the acute phase of infection, antigens are usually detectable in upper respiratory tract specimens.

The US Food and Drug Administration (FDA) granted Emergency Use Authorization for the BOSONTM Rapid SARS-CoV-2 Antigen Test Card (Home Test) on April 6, 2022. Global Technology Foundation is a fully authorized independent distributor of Boson Biotechnology Co., Ltd. throughout North America. It has the ability to supply government and private buyers with a monthly supply of 30-40 million boxes. The quotation on this page is only for the USA .Sales, DDP supply, accept TT payment.The BOSONTM� Rapid SARS-CoV-2 Antigen Test Card (Home Test) has been sold to Europe, Southeast Asia, Australia, Canada and other countries, with excellent product quality and service.  The test gained substantial popularity among users

INVBIO Covid Antigen Ag saliva rapid test card Sensitivity: 97.1% Specificity: 99% Agreement: 99.57% 10 miuntes to get the result. MOQ for each: 500 tests, 25 tests/box,

CE0197 --> WE HAVE THE CE certificate. WHY US : * Right price. * Excellent distribution. * No middle man. * Someone on the spot. * Boat / Plane. We can handle very large numbers - WOULD YOU BE THE FIRST ? - ORDER NOW, WHILE WE CAN STILL DELIVER ON TIME !!! 15days after Payment ( for now ). Stay Safe

This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

We offer wide range of reasonable and CE certified SARS COV-2 antigen test kits across Europe and worldwide. For further details please quote your target price , minimum or maximum order quantity, delivery time and location

The current test kit is based on specific antibody antigen reaction and immunoassay technique. The test card contains a gold labeled novel coronavirus N protein monoclonal antibody p re coated on the binding pad and a paired novel coronavirus N protein monoclonal antibodies fixed in the test line (T) and corresponding antibodies in the quality control line (C). During the test, the N protein in the specimen binds to the gold-labeled nove lcoronavirus N protein antibody pre-coated on the binding pad, and the conjugate moves upward under the capillary effect, and then is trapped by N protein monoclonal antibody conjugate fixed in the Test Line (T). The higher the N protein content in the specimen, the more conjugates are trapped, and the darker the color of the Test Line (T). If there is no novel coronavirus in the specimen or the virus content is below the detection limit, no colour appears in the Test Line (T). A purple red band will app ear in the Control Line (C) regardless of whether there is a virus in the specimen. The purple red band that appears in the Control Line (C) is the criteria for determining whether there is enough specimen and whether the chromatography process is normal.

Product # - 2402 SKU - K02432-52-2186-323 Product Name - Sneltest Covid Antigeen saliva merk GR Biotech Description - "Rapid test Covid Antigen Saliva test brand GR Biotech 10 pieces Delivers highly accurate results in just minutes, costs only a fraction of what a PCR test does and saves laboratory capacity - a chromatographic lateral=flow immunoassay - checks for protein fragments of the virus and thus for its direct, physical presence in the body. It is performed using saliva collection. This is extracted into a buffer solution and then dripped onto the test cassette. A qualitative result is ready in less than 20 minutes. specification 15 minutes rapid detection CE-IVD marked Pack of 10" Price / SKU - $49.88 1. MOQ is 1 pallet ( 700 boxes ) 2. The price is valid until 2 week

This kit works by immune chromatography. The sample moves with capillary action to move forward along the test card. If the sample contains novel coronavirus antigen, the antigens will bind with colloidal gold labeling will be coronavirus monoclonal antigen, the immune complex will be membrane fixed will be coronavirus monoclonal antibody capture, form the purple line, display will be coronavirus antigen positive; If the line does not show color, the negative result will be displayed. The test card also contains a quality control line C, which shall appear in magenta regardless of whether there is a detection line.

AIVD Biotechs COVID-19 Ag test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein (NP) antigen from SARS-CoV-2 in direct nasal swabs from individuals suspected of COVID-19. Description This kit utilizes the principle of latex bead immunochromatography to qualitatively detect the new coronavirus (COVID-19) Np antigen in human nasal swabs. Lateral flow immunochromatographic assay provides an easy workflow, short turnaround time, and rapid diagnosis of COVID-19 suspected patients. The test contains latex bead conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the test lines (T). If SARS-CoV-2 antigen is present in the specimen, a visible band appears on the test lines (T) as antibody-antigen-antibody latex bead complex forms. The control line (C) is used for procedural control and should always appear if the test is performed correctly. This method does not require expensive medical instruments and consumables. Just take the specimen and add it to the sample well. If sample contains the antigen, it will interact with the latex bead-labeled COVID-19 anti-SARS-COV-2 NP antibodies on the conjugate pad. Required components 1. A foil pouch with a desiccant and a single-use test card, 1 piece 3. Sterile swab, 1 piece 3. Extraction buffer tube (1 ml), 1 tube. 4. Instructions for use, 1 piece. Specimen requirements: 1. Nasopharyngeal swab specimen. 2.Specimen should be tested as soon as possible upon collection. If the sample has to be stored, store the swab sample at room temperature for up to 1 hour or 2~8â?? for up to 4 hours prior to testing. Specimen preparation 1. Insert the extraction buffer tube into the tube rack, make sure that the sample tube is firmly upright and touches the bottom of the rack. 2. Insert the swab into an extraction buffer tube. 3. Gently stir the swab in the tube, and then left swab inside the tube for 1 minute or Mix on the vortex mixer for about 30 seconds, 4. The sample should be tested immediately after collection. If it cannot be tested in time, it should be stored in the virus transport matrix. The specimens can be stored at 2-8C for 4 hours Basic Protocol Step 1: If the sample is refrigerated, remove the sample to be tested and the required reagents from the storage conditions, equilibrate to room temperature (15~30C) Step 2: When preparing to test, open the aluminum foil bag, take out the test card, and lay it flat on a table. Step 3: Mark the sample number on the test card, Step 4: Using pipette add 50ul of the sample into a sample well on the device, Step 5: Read the result within 15 minutes, Please read the result after 15 minutes. After observing and recording the result, please discard the test card to avoid affecting the result judgment. Do not read test results after 30 minutes. It may give false results.

Rapid sars cov 2 antigen test.

Flowflex sars cov 2 antigen rapid test.

Livzon Rapid Test for SARS-CoV-2 Antigen (Lateral Flow) Livzon Rapid Test for SARS-CoV-2 Antigen (Lateral Flow) is used for in vitro qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal swabs, oropharyngeal swabs and nasal swabs from individuals who are suspected of SARS-CoV-2 by their healthcare provider within the first seven days of symptom onset.